Key result
Pre-statin pharmacogenetic testing achieves high feasibility with ~85% provider enrollment in I-PICC.
Answers are grounded in this paper and cite their sources.
Pragmatic clinical trials (PCTs) have an established presence in clinical research and yet have only recently garnered attention within the landscape of genomic medicine. Using the PRagmatic-Explanatory Continuum Indicator Summary 2 (PRECIS-2) as a framework, this paper illustrates the application of PCT principles to The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study, a trial of pharmacogenetic testing prior to statin initiation for cardiovascular disease prevention in primary care. The trial achieved high engagement with providers (85% enrolled of those approached) and enrolled a representative sample of participants for which statin therapy would be recommended. The I-PICC Study has a high level of pragmatism, which should enhance the generalizability of its findings. The PRECIS-2 may be useful in the design and evaluation of PCTs of genomic medicine interventions, contributing to the generation of evidence that can bridge the gap between genomics innovation and clinical adoption.
No takes yet. Share an insight, caveat, or question.
Brunette et al. (2019) studied Cardiovascular disease prevention. Pharmacogenetic testing prior to statin initiation was evaluated. The I-PICC pragmatic clinical trial of pharmacogenetic testing prior to statin initiation achieved high provider engagement, with 85% of approached providers enrolling in the study.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: